Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug4532 | insurance navigation Wiki | 0.71 |
| drug1806 | Hydroxychloroquine Sulfate Regular dose Wiki | 0.50 |
| drug1805 | Hydroxychloroquine Sulfate Loading Dose Wiki | 0.50 |
Navigate: Correlations HPO
There are 2 clinical trials
This research study evaluates the safety and effectiveness for the use of convalescent plasma transfusion as a treatment option for novel coronavirus SARS-CoV-2 infection (COVID-19). Donors who have recovered from COVID-19 with high antibody levels to the CoV-2 virus will donate plasma at a Mississippi Blood Services facility. Recipients with COIVD-19 who have severe or life threatening conditions will receive plasma from those persons who have recovered from COVID-19.
Description: Change in pre-transfusion respiratory status compared to Day 3 respiratory status measured by PaO2/FiO2.
Measure: Change in PaO2/FiO2 after CCP transfusion. Time: 3 DaysDescription: Change in pre-transfusion respiratory status compared to Day 3 respiratory status measured by pulse oximetry.
Measure: Change in pulse oximetry status after CCP transfusion. Time: 3 DaysDescription: Change in pre-transfusion respiratory status compared to Day 3 respiratory status measured by aO2.
Measure: Change in aO2 after CCP transfusion. Time: 3 DaysDescription: Change in pre-transfusion respiratory status compared to Day 3 respiratory status measured by respiratory rate.
Measure: Change in respiratory rate after CCP transfusion. Time: 3 DaysDescription: Change in pre-transfusion respiratory status compared to Day 3 respiratory status measured by intubation status.
Measure: Change in intubation status after CCP transfusion. Time: 3 DaysDescription: Change in SOFA score pre-transfusion to Days 1, 3, 7, and 28 post-transfusion.
Measure: Change in Sequential Organ Failure Assessment (SOFA). Time: Days 1, 3, 7, and 28Description: Change in 8-point ordinal clinical deterioration scale pre-transfusion to Days 1, 3, 7, and 28 post-transfusion. The 8-point ordinal scale measured by: 8-death, 7-ventilation in addition to ECMO, CRRT and/or vasopressor; 6-intubation and mechanical ventilation; 5-non-invasive mechanical ventilation or high flow oxygen 4- supplemental oxygen by mask or nasal cannula; 3- hospitalization without supplemental oxygen; 2- limitation of activities and 1- no limitation of activities, discharge from hospital.
Measure: Change in 8-point ordinal clinical deterioration scale. Time: Days 1, 3, 7, and 28Description: Total length of stay in ICU/hospital.
Measure: Length of ICU/hospital stay. Time: Days 1, 3, 7, and 28Description: Presence of any signs or symptoms of plasma transfusion reactions at Days 1, 3, 7, and 28 post-transfusion.
Measure: Development of plasma transfusion reactions. Time: Days 1, 3, 7, and 28Description: Presence of any signs or symptoms of immune complex disorders (fever spike, urticarial lesion, arthralgias, myalgias, hematuria, non IgE-mediated anaphylaxis) at Days 1, 3, 7, and 28 post-transfusion.
Measure: Development of immune complex disorders. Time: Days 1, 3, 7, and 28Description: Change in anti CoV-2 IgM and IgG levels pre-transfusion compared to levels on Days 1, 3, 7, and 28 post-transfusion.
Measure: Change in anti CoV-2 IgM and IgG levels. Time: Days 1, 3, 7, and 28Currently there are no proven treatments or vaccines for COVID-19 and care of the COVID patients is largely supportive involving treatment of symptoms such as fever with antipyretics, secondary bacterial chest infection with antibiotics and meticulous management of comorbid conditions. Several repurposed and new drugs have been investigated for treatment of COVID-19, however, none have been confirmed to be efficacious. These drugs include the antimalarials (chloroquine and hydroxychloroquine), antivirals such as remdesivir and favipiravir and antiretroviral combination therapies such lopinavir/ritonavir. There is emerging evidence to support the use of COVID convalescent plasma for the treatment of COVID-19. There is need to leverage the blood transfusion services in countries and this is beginning to happen on the continent.
Description: The primary end point will be time to viral clearance (RT-PCR negativity).
Measure: Time to viral clearance (RT-PCR negativity) Time: 28 daysDescription: time to symptom resolution (resolution of the major COVID-19 symptoms of fever, cough, and shortness of breath, rhinorrhea and fatigue)
Measure: Time to symptom resolution Time: 28 daysDescription: Safety of convalescent plasma as determined by clinical manifestations eg Skin or mucous membrane manifestations, respiratory compromise, Decrease in systolic blood pressure to <90 mmHg or >30% decrease from baseline or a diastolic drop of >30% from baseline, Tachycardia with an increase in resting heart rate to >130 bpm; or bradycardia <40 bpm that is associated with dizziness, nausea or feeling faint, Any other symptom which the good clinical judgment of the physician warrants halting the infusion (i.e., rapid onset of gastrointestinal symptoms, etc.)
Measure: Number of participants reporting an adverse event as evidenced by clinical manifestations Time: 28 daysAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports